Overview

Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis

Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if natalizumab in combination with Glatiramer Acetate (GA) is safe and effective in delaying progression of individuals diagnosed with relapsing-remitting Multiple Sclerosis (MS).
Phase:
Phase 2
Details
Lead Sponsor:
Biogen
Collaborator:
Elan Pharmaceuticals
Treatments:
Glatiramer Acetate
Natalizumab